Navigation Links
Vaccine patent portfolio licensed from UK Ministry of Defence
Date:2/19/2009

TORONTO, Feb. 19 /PRNewswire/ - Defyrus Inc. today announced the signing an exclusive, worldwide license to a patent portfolio created by the United Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by Ploughshare Innovation Ltd, Dstl's commercialization company. These patents form the intellectual property foundation of the Company's vaccine product development programs. Defyrus and Ploughshare Innovation Ltd plan to expand their commercial interaction in 2009 to include preclinical safety and efficacy studies as part of the Company's vaccine development program. The commercial terms of the license were not disclosed.

The licensed technology of 27 issued & pending international patents, describes the production of multi-valent vaccines for the treatment of alpha-viral infections resulting from bioterrorism or endemic disease. These highly infectious, mosquito-borne encephalitis viruses pose a serious risk to people and livestock for which no vaccine or therapy exists.

"Dstl has pioneered the investigation of effective medical countermeasures (e.g. vaccines and drugs) for the treatment of a number of important biological diseases that are potential biological warfare threats. Their unique approach to vaccine development and compelling animal efficacy data for viral encephalitis made this license attractive" commented Dr. Jeffrey D. Turner, President & CEO of Defyrus, "We see tremendous synergy in levering investor capital with successful Government R&D programs to drive cost-effective, rapid drug development forward. Improving our capability to respond to viral threats from endemic disease or biological warfare is our mission and represents a significant contribution to protecting the international community from dangerous pathogens".

"Defyrus' business model has the hallmark of a true public-private collaboration. In licensing Dstl's technology to Defyrus, whose management team have a proven track rec
'/>"/>

SOURCE Defyrus Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 Corporate Executives ... of MEBC, an Alliance Award for excellence in ... FOCUS 2015, JDA’s annual user conference which brought ... and wholesale distribution sectors. This award recognizes MEBC, ... receiving services that advance their supply chain performance ...
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... Los Angeles (PRWEB) May 06, 2015 ... WaterAid, the #1 ranked international water, sanitation and hygiene ... work for communities across the world and it brings ... Lindsey Carnett, CEO of Marketing Maven. “The ongoing relationship ... the opportunities available for people to learn about and ...
(Date:5/6/2015)... Waltham, MA (PRWEB) May 06, 2015 ... information for healthcare professionals and students, announced today that ... UpToDate®, 94% confirmed that use of the clinical decision ... Additionally, by the end of 2014, UpToDate users in ... million clinical topics per month, on average. In Germany ...
(Date:5/6/2015)... TU-Automotive has opened press registration for TU-Automotive ... it to the headlines of major publications world-wide. With ... and Hyundai ready to share their visions for the ... way for press to go behind the scenes and ... TU-Automotive said “This year we’re releasing a preview of ...
Breaking Medicine News(10 mins):Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Press Registration for TU-Automotive Detroit Now Open 2
... LUGANO, Switzerland, September 9 As part of the ... as new,CEO in the American subsidiary, Helsinn Therapeutics (U.S.) ... the recently acquired,Helsinn Therapeutics, and has held leadership positions ... in Research. , Moreover, Helsinn ...
... ... with medically inoperable lung cancer. , ... Phoenix, Arizona (Vocus) September 9, 2009 -- Today, DoctorFinders.com ( http://doctorfinders.com/ ... medically inoperable lung cancer ., , , , ,Medically inoperable cancer can be ...
... ... Cosmetic Dentistry, well known for dental care as well as cosmetic and sedation dentistry, ... ... 9, 2009 -- Raleigh Comprehensive and Cosmetic Dentistry, led by Dr. Robert L. Williamson ...
... , - Choosing a More Appropriate ... to Improvement , The first results of ... presented today at the 6th congress,of the European Federation of Chapters ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 ) , ...
... light, 300 million metres per second, was long thought ... matter and energy but recent research in the area ... manipulate light to some ingenious and hugely lucrative ends. ... perfect images of distant galaxies or detailed representations inside ...
... infectious bacteria in an experimental system, researchers at University ... in the body the bacteria go giving an ... to the development of more targeted treatments. At ... Edinburgh, Dr Cormac Gahan described how his research team ...
Cached Medicine News:Health News:New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc. 2Health News:CyberKnife Treatment for Medically Inoperable Lung Cancer 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 2Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 2Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 3Health News:Light at the speed of a bicycle and much more 2
(Date:5/6/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... community to review the clinical development strategy for ... on Friday, May 8, 2015. Topics will include ... planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... INCLINE VILLAGE, Nev., May 6, 2015 PDL BioPharma, ... results for the first quarter ended March 31, 2015. ... 2015 increased nine percent to $149.7 million from $136.8 ... the quarter ended March 31, 2015 included $127.8 million ... the Queen et al. patents, $11.4 million in net ...
(Date:5/6/2015)... 6, 2015 Lannett Company, Inc. (NYSE: ... 2015 third quarter ended March 31, 2015.  ... rose 24% to $99.4 million from $80.0 million in ... $75.6 million, or 76% of net sales, from $56.1 ... (R&D) expenses decreased to $9.2 million from $10.6 million ...
Breaking Medicine Technology:Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8
... Schein, Inc. (Nasdaq: HSIC ), the largest provider ... today that it will release its third quarter 2010 financial ... 2010, and will provide a live webcast of its earnings ... Eastern Daylight Time. Speakers on the call will include Stanley ...
... PITTSBURGH, Oct. 15 Mylan Inc. (Nasdaq: ... Inc. received final approvals from the U.S. Food and ... (ANDAs) for the generic versions of Hyzaar® Tablets, 50 ... 25 mg, 50 mg and 100 mg, both antihypertensives. ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar® 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: